2012
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1093/ejcts/ezr027
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22011780
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1010-7940
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1873-734X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_76D477AFF1C16
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
E. Ferrari, « Transapical aortic 'valve-in-valve' procedure for degenerated stented bioprosthesis. », Serveur académique Lausannois, ID : 10.1093/ejcts/ezr027
Standard surgical aortic valve replacement with a biological prosthesis remains the treatment of choice for low- and mid-risk elderly patients (traditionally >65 years of age) suffering from severe symptomatic aortic valve stenosis or insufficiency, and for young patients with formal contraindications to long-lasting anticoagulation. Unfortunately, despite the fact that several technical improvements have noticeably improved the resistance of pericardial and bovine bioprostheses to leaflet calcifications and ruptures, the risk of early valve failure with rapid degeneration still exists, especially for patients under haemodialysis and for patients